TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06131216: Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-2022 Injection Alone or in Combination With Other Anti-tumor Treatments in Patients With Advanced Malignant Tumors

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 116 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06131216 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06131216 Rescue Dossier →